This standard includes antifungal agent selection, preparation of antifungal stock solutions and dilutions for testing, test procedure implementation and interpretation, and quality control requirements for susceptibility testing of filamentous fungi (moulds) that cause invasive and cutaneous fungal infections.

A standard for global application developed through the Clinical and Laboratory Standards Institute consensus process.
Clinical and Laboratory Standards Institute

Setting the standard for quality in medical laboratory testing around the world.

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI’s consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI Standards Development Policies and Processes, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: +1.610.688.0100
F: +1.610.688.0700
www.clsi.org
standard@clsi.org
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi

Barbara D. Alexander, MD, MHS
Gary W. Procop, MD, MS
Philippe Dufresne, PhD (RMCCM)
Ana Espinel-Ingroff, PhD, MS
Jeff Fuller, PhD, FCCM, D(ABMM)
Mahmoud A. Ghannoum, PhD, EMBA, FIDSA
Kimberly E. Hanson, MD, MHS
Denise Holliday, MT(ASCP)
Nicole M. Holliday, MT
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA
Audrey N. Schuetz, MD, MPH, D(ABMM)
Nathan P. Wiederhold, PharmD
Adrian M. Zelazny, PhD, D(ABMM)

Abstract

Clinical and Laboratory Standards Institute standard M38—Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi describes a method for testing the susceptibility to antifungal agents of filamentous fungi (nondermatophyte and dermatophyte moulds) that cause invasive and/or cutaneous fungal infections. Antifungal agent selection, preparation of antifungal stock solutions and dilutions for testing, test procedure implementation and interpretation, and the purpose and implementation of QC procedures are discussed. A careful examination of manufacturer and user responsibilities in QC is also presented. In addition, a brief discussion regarding newly defined epidemiological cutoff values for certain Aspergillus spp. and species complexes are included.

## Contents

Abstract .................................................................................................................................................... i
Committee Membership ........................................................................................................................ iii
Foreword .............................................................................................................................................. vii

**Chapter 1: Introduction** ....................................................................................................................... 1
  1.1 Scope ............................................................................................................................................. 1
  1.2 Background ................................................................................................................................. 2
  1.3 Standard Precautions ................................................................................................................ 2
  1.4 Terminology ............................................................................................................................... 2

**Chapter 2: Preparing for Antifungal Susceptibility Testing** ............................................................... 7
  2.1 Indications for Performing Antifungal Susceptibility Tests ......................................................... 7
  2.2 Selecting Antifungal Agents for Routine Testing and Reporting .................................................. 8

**Chapter 3: Antifungal Broth Dilution Susceptibility Testing Process for Filamentous Fungi** .......... 11
  3.1 Preparing Antifungal Agents ...................................................................................................... 13
  3.2 Testing Procedures .................................................................................................................... 16
  3.3 Reading Minimal Inhibitory Concentration and Minimal Effective Concentration Results ....... 22
  3.4 Interpreting Results .................................................................................................................. 24

**Chapter 4: Quality System Essential: Process Management – Quality Control** .............................. 27
  4.1 Quality Control Purpose ............................................................................................................ 27
  4.2 Quality Control Responsibilities .............................................................................................. 27
  4.3 Selecting Reference Strains ....................................................................................................... 28
  4.4 Storing Reference Strains ......................................................................................................... 28
  4.5 Controlling Media Batches and Plasticware Lots ..................................................................... 30
  4.6 Quality Control Frequency ....................................................................................................... 31
  4.7 Other Quality Control Procedures ............................................................................................ 32

**Chapter 5: Conclusion** ....................................................................................................................... 34

**Chapter 6: Supplemental Information** ............................................................................................................. 34
References ................................................................................................................................................. 35

Appendix A. Preparing Dilution Series of Water-Insoluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests for Nondermatophytes ......................................................... 39

Appendix B. Preparing Dilution Series of Water-Insoluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests of Dermatophytes ........................................................................... 40

Appendix C. Composition of Roswell Park Memorial Institute 1640 Culture Medium (With Glutamine and Phenol Red but Without Bicarbonate) ................................................................. 41

Appendix D. Preparing Roswell Park Memorial Institute 1640 Culture Medium ................................. 42

Appendix E. Preparing Dilution Series of Water-Soluble Antifungal Agents to Be Used in Broth Dilution Susceptibility Tests of Filamentous Fungi and Dermatophytes .............................. 43

Appendix F. Preparing Oatmeal Agar ................................................................................................. 44
Appendix G. Minimal Effective Concentrations of Caspofungin and Anidulafungin ....................... 45
Contents (Continued)

The Quality Management System Approach ...........................................................................48
Related CLSI Reference Materials .........................................................................................49
Foreword

With the increased incidence of systemic fungal infections and the growing number of available antifungal agents, laboratory guidance for selecting antifungal therapy has gained greater attention. The Subcommittee on Antifungal Susceptibility Tests concluded that a reproducible reference procedure for the antifungal susceptibility testing of filamentous fungi (molds) would be useful. Accordingly, several studies were conducted to refine the methodology for performing non-dermatophyte mould susceptibility testing. The resulting consensus method was published in 2002 as M38, and a revision published in 2008.

In the previous edition of this standard, supplemental material (QC data for mould isolates as well as echinocandin testing guidelines) was incorporated and guidelines for testing dermatophyte moulds were provided. Since then, in the absence of breakpoints for mould testing, epidemiological cutoff values (ECVs) for distinguishing wild-type and non-wild-type isolates (those with intrinsic or acquired known resistance mechanisms or gene mutations) have been defined for some species and species complexes of Aspergillus (see CLSI documents M57 and M59). Although a discussion regarding breakpoints was introduced in the previous edition of M38, breakpoints have not been established by CLSI for mould testing. ECV data and recommendations for their development are found in CLSI documents M57 and M59. QC data for testing mould isolates, as well as other testing guidelines, have been omitted from this edition of M38 and incorporated into the newly created CLSI document M61, which combines supplemental material for this standard and CLSI document M51.

Overview of Changes

This standard replaces the previous edition of the approved standard, M38-A2, published in 2008. Several changes were made in this edition, including:

- **General:**
  - Revised document format and organization to reflect the CLSI quality system essential and path of workflow document templates and the updated CLSI style
  - Updated references to the previous informational supplement (M51-S1) to reflect CLSI document M61, the new supplement for broth dilution and disk diffusion mould susceptibility testing
  - Added references to epidemiological cutoff values and CLSI documents M57 and M59

- **Subchapter 1.4.2, Definitions:**
  - Revised the breakpoint and interpretive category definitions for consistency with other CLSI antimicrobial susceptibility testing documents.
  - Added definitions for “wild-type” and “non-wild-type”

- **Chapter 2, Preparing for Antifungal Susceptibility Testing:**
  - Added new indications for testing of filamentous fungi, with a discussion of resistance in Aspergillus fumigatus originating from the natural environment

- **Chapter 3, Antifungal Broth Dilution Susceptibility Testing Process for Filamentous Fungi:**
  - Added an antifungal susceptibility testing process flow chart
  - Expanded the list of relevant drug concentrations to be tested for echinocandins
  - Replaced procedural text with step-action tables
M38, 3rd ed.

- Established guide for reading and interpreting results for filamentous fungi, including dermatophytes

- Modified text on reading results in Subchapter 3.4 to include new information on echinocandins and isavuconazole antifungal agents and minimal inhibitory concentration (MIC) and minimal effective concentration (MEC) comparison

- **Subchapter 4.6, Quality Control Frequency:**
  - Added a note for the preparation of *Candida* spp. QC strains (Subchapter 4.6.1)

- **Appendixes (Original Tables):**
  - Updated and moved the solvent list table from M38 to the new supplement, CLSI document M61\(^{18}\)
  - Moved the table providing the recommended MIC or MEC limits for QC and reference strains for broth dilution procedures from M38 to the combined supplement, CLSI document M61\(^{18}\)
  - Corrected Appendix C (Composition of Roswell Park Memorial Institute 1640 Culture Medium) to provide a single riboflavin concentration (0.0002 g/L), as found in CLSI document M27\(^{20}\)
  - Harmonized dilution schemes for dermatophyte and nondermatophyte isolates with those in CLSI document M27\(^{20}\) and revised to encompass the full dilution ranges recommended
  - Deleted the procedure for preparing a 0.5 McFarland (barium sulfate) standard and added a note referring to CLSI document M27\(^{20}\) for *Candida* spp. QC strains to Subchapter 4.6.1

**NOTE:** The content of this standard is supported by the CLSI consensus process and does not necessarily reflect the views of any single individual or organization.

**Key Words**

Antifungal agent, broth microdilution, dermatophytes, epidemiological cutoff value, filamentous fungi, mould, non-wild-type, susceptibility testing, wild-type
Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi

Chapter 1: Introduction

This chapter includes:

- Standard’s scope and applicable exclusions
- Background information pertinent to the standard’s content
- Standard precautions information
- “Note on Terminology” that highlights particular use and/or variation in use of terms and/or definitions
- Terms and definitions used in the standard
- Abbreviations and acronyms used in the standard

1.1 Scope

This standard describes the reference broth microdilution testing method for antifungal susceptibility testing of filamentous fungi (moulds) that cause invasive and/or cutaneous fungal infections.1-10 This standard also covers testing conditions, including inoculum preparation and inoculum size, incubation time and temperature, media formulation, and end-point determination criteria.1-9 QC reference ranges and limits and specific epidemiological cutoff values (ECVs) are summarized in the current editions of CLSI documents M6118 and M59,12 respectively.5,8-10,13-17

The intended audience includes medical laboratory personnel, clinicians, and microbiologists who routinely perform antifungal susceptibility testing and use antifungal susceptibility testing results to select suitable antifungal therapy, as well as those involved in emerging resistance surveillance. The reference method is also useful for establishing ECVs and developing and validating alternate commercial methods for determining antifungal susceptibility of filamentous fungi. Therefore, the standard is also of interest for both diagnostic and pharmaceutical companies and their regulatory counterparts.

This method has not been evaluated in studies of the yeast or mould forms of dimorphic fungi, such as Blastomyces dermatitidis, Coccidioides immitis/posadasii, Histoplasma capsulatum, or Talaromyces marneffei (Penicillium marneffei), and has been evaluated only for the mycelial form of Sporothrix schenckii species complex.1 This method also has not been used in studies of dermatophytes with the echinocandins or nondermatophyte moulds with ciclopirox, griseofulvin, or terbinafine.

Antifungal susceptibility testing of other filamentous fungi that cause infections may also be tested by this method but have not been standardized and evaluated in collaborative studies. The appropriate testing parameters such as inoculum and incubation time for those fungi are unknown.

Commerially available susceptibility test systems are out of scope for this standard. It is recommended that users of these systems refer to the manufacturer’s instructions as outlined in the package insert.
1.2 Background

The method described in this standard is intended for testing common filamentous fungi, including the dermatophytes \( (Trichophyton\) spp., \( Microsporum\) spp., and \( Epidermophyton\) spp.),\(^9\) more prevalent \( Aspergillus\) spp. and species complexes, \( Fusarium\) spp. and species complexes, \( Rhizopus\) spp. and other Mucorales (Zygomycetes),\(^{21}\) \( Lomentospora\) \( prolificans\) \( (Scedosporium\) \( prolificans)\),\(^{22}\) the mycelial form of species included in the \( S.\) \( schenckii\) complex, and dematiaceous (phaeoid [black]) moulds.\(^{23}\)

This standard provides a reference method developed through a consensus process to facilitate agreement among laboratories in measuring mould susceptibility to antifungal agents. An important use of a reference method is to provide a standard basis from which other methods can be developed, which also results in interlaboratory agreement within specified ranges. Such methods might have particular advantages, such as ease of performance, economy, or production of more rapid results; therefore, their development could be highly desirable. To the extent that any method produces results concordant with this reference method, it would be considered to conform to this standard.

1.3 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all known infectious agents and thus are more comprehensive than universal precautions, which are intended to apply only to transmission of bloodborne pathogens. Published guidelines are available that discuss the daily operations of diagnostic medicine in humans and animals while encouraging a culture of safety in the laboratory.\(^{24}\) For specific precautions for preventing the laboratory transmission of all known infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all known infectious diseases, refer to CLSI document M29.\(^{25}\)

1.4 Terminology

1.4.1 A Note on Terminology

CLSI, as a global leader in standardization, is firmly committed to achieving global harmonization whenever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in different countries and regions and that legally required use of terms, regional usage, and different consensus timelines are all important considerations in the harmonization process. CLSI recognizes its important role in these efforts, and its consensus process focuses on harmonization of terms to facilitate the global application of standards and guidelines.

Fungal taxonomy has undergone major changes in recent years with the dual (asexual and sexual stages) nomenclature having been abolished and the constant reclassification and renaming of fungal species that result from improved molecular characterization.\(^{26}\) Species names listed in M38 are revised to reflect the most recent taxonomic changes based on classification according to DNA bar coding at the time of publication. For more information regarding updated fungal species reclassification, refer to publicly available information.\(^{27}\)

NOTE: At the time of this standard’s publication, breakpoints are not yet available for any antifungal agent against mould species; however, ECVs based solely on in vitro data have been established (see CLSI document M59).\(^{12}\) Currently, breakpoints apply only to some \( Candida\) spp. and antifungal agent combinations. Definitions for breakpoints and interpretive categories are provided in Subchapter 1.4.2 in the event that breakpoints are published for filamentous fungi in the future.
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in the development of standards and guidelines that facilitates project management, defines a document structure using a template, and provides a process to identify needed documents. The QMS approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are:

- Organization
- Customer Focus
- Facilities and Safety
- Personnel
- Purchasing and Inventory
- Equipment
- Process Management
- Documents and Records
- Information Management
- Nonconforming Event Management
- Assessments
- Continual Improvement

M38 covers the QSE indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.

Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver their services, namely quality laboratory information.

M38 covers the medical laboratory path of workflow processes indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section.
**Related CLSI Reference Materials**

<table>
<thead>
<tr>
<th>CLSI Document</th>
<th>Title</th>
<th>Edition</th>
<th>Year</th>
</tr>
</thead>
</table>

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at clsi.org/eCLIPSE.

For more information, visit www.clsi.org today.